Peer Reviewed Study Reveals Benefits of ClearFlow’s PleuraFlow ACT System

September 27, 2017, 8:23 am

≫ Next: Studies Recognizing the Importance of Limiting Retained Blood to Prevent Postoperative Atrial Fibrillation Featured on January Cover of Annals of Thoracic Surgery

$

0

0

–Study Supports Previously Published Data on Reduction of Postoperative Atrial Fibrillation After Heart Surgery Among Patients Treated with PleuraFlow Active Clearance Technology– Anaheim, CA – September 27, 2017—ClearFlow Inc., a medical device company based in Anaheim, California, has announced the publication of significantly positive results in a study evaluating the company’s PleuraFlow® Active Clearance Technology® System. Data from a peer-reviewed clinical study indicating a marked reduction in Postoperative Atrial Fibrillation (POAF) among patients with active clearance of chest tubes after heart surgery was published in the August edition of the Journal of Thoracic and Cardiovascular Surgery. The study is titled “Examining the impact of active clearance of chest drainage catheters

The post Peer Reviewed Study Reveals Benefits of ClearFlow’s PleuraFlow ACT System appeared first on ClearFlow.

---

Studies Recognizing the Importance of Limiting Retained Blood to Prevent Postoperative Atrial Fibrillation Featured on January Cover of Annals of Thoracic Surgery

February 1, 2018, 9:03 am

≫ Next: ClearFlow Reports: ERAS Cardiac Surgery Recommends Active Tube Clearance Methodology in Consensus Statement Presented at the 98th Annual Meeting of The American Association for Thoracic Surgeons

≪ Previous: Peer Reviewed Study Reveals Benefits of ClearFlow’s PleuraFlow ACT System

$

0

0

–ClearFlow spokespeople cite review article as latest piece of mounting evidence pertaining to urgent need for managing retained blood after surgery– Anaheim, CA – February 1, 2018—ClearFlow Inc., a medical device company based in Anaheim, California, has announced that the cover of the January, 2018 issue of The Annals of Thoracic Surgery features a review article that elucidates the biological mechanisms by which retained shed mediastinal blood can trigger postoperative atrial fibrillation (POAF) in susceptible individuals as well as how this could represent a new target for prevention of POAF. The article can be viewed online here: http://www.annalsthoracicsurgery.org/article/S0003-4975(17)31095-0/fulltext The article’s author group is comprised of key opinion leaders on the

The post Studies Recognizing the Importance of Limiting Retained Blood to Prevent Postoperative Atrial Fibrillation Featured on January Cover of Annals of Thoracic Surgery appeared first on ClearFlow.

ClearFlow Reports: ERAS Cardiac Surgery Recommends Active Tube Clearance Methodology in Consensus Statement Presented at the 98th Annual Meeting of The American Association for Thoracic Surgeons

May 2, 2018, 11:24 am

≫ Next: ERAS Cardiac Surgery Featured at Dedicated Session at European Association for Cardio-Thoracic Surgery in Milan

≪ Previous: Studies Recognizing the Importance of Limiting Retained Blood to Prevent Postoperative Atrial Fibrillation Featured on January Cover of Annals of Thoracic Surgery

$

0

0

  San Diego, California – May 2, 2018 – ClearFlow Inc. has announced that an international society of leading heart surgeons known as ERAS® Cardiac Surgery presented evidenced-based expert consensus statements at the 98th annual meeting of the American Association for Thoracic Surgeons on April 28, 2018. Amongst key recommendations to promote enhanced patient outcomes after cardiac surgery is the use of Active Clearance techniques to maintain chest tube patency.  The PleuraFlow® ACT® System is the only FDA cleared device with the indication to prevent or minimize retained blood in patients recovering from heart surgery. The PleuraFlow ACT System is indicated for use during cardiothoracic surgical procedures and chest trauma.

The post ClearFlow Reports: ERAS Cardiac Surgery Recommends Active Tube Clearance Methodology in Consensus Statement Presented at the 98th Annual Meeting of The American Association for Thoracic Surgeons appeared first on ClearFlow.

ERAS Cardiac Surgery Featured at Dedicated Session at European Association for Cardio-Thoracic Surgery in Milan

October 31, 2018, 3:41 pm

≫ Next: ClearFlow Announces Additional Positive US Clinical Trial Results at the 2018 NTI Critical Care Exposition

≪ Previous: ClearFlow Reports: ERAS Cardiac Surgery Recommends Active Tube Clearance Methodology in Consensus Statement Presented at the 98th Annual Meeting of The American Association for Thoracic Surgeons

$

0

0

ERAS Cardiac Surgery Featured at Dedicated Session at European Association for Cardio-Thoracic Surgery in Milan   Springfield, MA — October 24, 2018 — The ERAS Cardiac Surgery Society presented its recent consensus statement at the 32nd European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Milan, Italy, last week as part of an educational session.   This dedicated ERAS Cardiac Surgery session was held during EACTS, the world’s largest cardiothoracic surgery focused professional conference with international speakers across all subspecialties.   ERAS Cardiac Surgery is a patient safety organization with the mission to facilitate optimization of perioperative care of cardiac surgical patients through collaborative discovery, analysis, expert consensus, and dissemination of best

The post ERAS Cardiac Surgery Featured at Dedicated Session at European Association for Cardio-Thoracic Surgery in Milan appeared first on ClearFlow.

ClearFlow Announces Additional Positive US Clinical Trial Results at the 2018 NTI Critical Care Exposition

May 29, 2018, 8:41 am

≫ Next: ClearFlow Awarded Chest Drainage Products Agreement with Premier

≪ Previous: ERAS Cardiac Surgery Featured at Dedicated Session at European Association for Cardio-Thoracic Surgery in Milan

$

0

0

Boston, MA – May 29th, 2018 — ClearFlow, Inc., a medical device company based in Anaheim, California, has announced that positive clinical trial results were presented at the National Teaching Institute (NTI) & Critical Care Exposition 2018 annual meeting on May 23rd, 2018 in Boston, MA. The findings were presented by the study principal investigator, Dr. Yvon Baribeau, of Catholic Medical Center in Manchester, New Hampshire, in a presentation titled “Active Clearance of Chest Drains Reduces Pleural Effusions and ICU Resources in patients undergoing Cardiac Surgery.” This data stems from a trial evaluating the use of the PleuraFlow® Active Clearance Technology® (ACT®) System to prevent retained blood complications in heart

The post ClearFlow Announces Additional Positive US Clinical Trial Results at the 2018 NTI Critical Care Exposition appeared first on ClearFlow.

ClearFlow Awarded Chest Drainage Products Agreement with Premier

August 21, 2018, 8:47 am

≫ Next: ClearFlow Announces Positive Randomized Controlled Trial Results and Inclusion in ERAS Guideline Recommendations

≪ Previous: ClearFlow Announces Additional Positive US Clinical Trial Results at the 2018 NTI Critical Care Exposition

$

0

0

Anaheim, CA – August 21, 2018— ClearFlow, Inc., a medical device company based in Anaheim, California, announced today that it has been awarded a group purchasing agreement for the Chest Drainage Products category with Premier.   Effective July 15th 2018, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for:   PleuraFlow Active Clearance Technology (ACT) System; PleuraFlow Active Clearance Technology (ACT) System with FlowGlide; and PleuraFlow POD – High Capacity Dry Thoracic Drainage Canister. “ClearFlow is proud to now be able to bring its Active Clearance Technology devices to Premier members under these new arrangements with one of

The post ClearFlow Awarded Chest Drainage Products Agreement with Premier appeared first on ClearFlow.

ClearFlow Announces Positive Randomized Controlled Trial Results and Inclusion in ERAS Guideline Recommendations

May 7, 2019, 8:51 am

≫ Next: New Published Clinical Trial Results Confirm that PleuraFlow Enables Improved Quality and Cost of Care for Cardiac Surgery Patients

≪ Previous: ClearFlow Awarded Chest Drainage Products Agreement with Premier

$

0

0

Anaheim, California–May 7, 2019–ClearFlow, Inc., a medical device company based in Anaheim, California, has announced that positive clinical trial results of its PleuraFlow® device were presented at the American Association for Thoracic Surgery (AATS) 99th Annual meeting on May 4 in Toronto, Canada.  This new data stems from a trial evaluating the use of ClearFlow’s PleuraFlow® Active Clearance Technology® (ACT®) System in heart surgery patients at the Montreal Heart Institute.   PleuraFlow is a medical device used at the bedside in the ICU that enables caregivers to actively maintain chest tube patency following cardiac surgery. A patent chest tube enables evacuation of blood and fluid from the operative site after

The post ClearFlow Announces Positive Randomized Controlled Trial Results and Inclusion in ERAS Guideline Recommendations appeared first on ClearFlow.

New Published Clinical Trial Results Confirm that PleuraFlow Enables Improved Quality and Cost of Care for Cardiac Surgery Patients

November 29, 2019, 7:53 am

≫ Next: PleuraFlow Shown to Enable Improved Outcomes for Cardiac Surgery Patients in New Clinical Study Results

≪ Previous: ClearFlow Announces Positive Randomized Controlled Trial Results and Inclusion in ERAS Guideline Recommendations

$

0

0

Reduction of Patient Complications and Hospital Resource Utilization After Heart Surgery Demonstrated with Use of the PleuraFlow ACT System   Irvine, CA – November 20, 2019 — ClearFlow, Inc., a medical device company based in Irvine, California, has announced positive clinical trial results published in the peer-reviewed Journal of Cardiothoracic Surgery.  The trial evaluated the use of the PleuraFlow® Active Clearance Technology® (ACT®) System in prevention of retained blood complications in heart surgery patients.   PleuraFlow is a medical device used at the bedside in the ICU that enables clinicians to proactively maintain chest tube patency following cardiac surgery without breaking the sterile field.  A patent chest tube enables evacuation of blood and fluid from the

The post New Published Clinical Trial Results Confirm that PleuraFlow Enables Improved Quality and Cost of Care for Cardiac Surgery Patients appeared first on ClearFlow.

---

PleuraFlow Shown to Enable Improved Outcomes for Cardiac Surgery Patients in New Clinical Study Results

October 20, 2020, 8:54 am

≫ Next: Randomized Clinical Trial Results Confirm PleuraFlow Reduces Take Back for Bleeding in Cardiac Surgery Patients

≪ Previous: New Published Clinical Trial Results Confirm that PleuraFlow Enables Improved Quality and Cost of Care for Cardiac Surgery Patients

$

0

0

Reduction of Patient Complications After Heart Surgery Demonstrated with Use of the ClearFlow’s PleuraFlow ACT System   Irvine, CA – October 20, 2020  — ClearFlow, Inc., a medical device company based in Irvine, California, has announced positive clinical trial results presented at the 2020 Virtual Program of the Annual Eastern Cardiothoracic Surgical Society Conference (ECTSS) on October 8th.  The trial evaluated the use of the ClearFlow’s PleuraFlow® Active Clearance Technology® (ACT®) System in the prevention of retained blood complications in heart surgery patients.   The findings, titled “Better Pericardial Drainage After Cardiac Surgery Leads to Better Outcomes,” were presented by Dr. Meghan Kelly of the Division of Cardiothoracic Surgery at Washington University School of

The post PleuraFlow Shown to Enable Improved Outcomes for Cardiac Surgery Patients in New Clinical Study Results appeared first on ClearFlow.

Randomized Clinical Trial Results Confirm PleuraFlow Reduces Take Back for Bleeding in Cardiac Surgery Patients

March 30, 2021, 9:43 am

≪ Previous: PleuraFlow Shown to Enable Improved Outcomes for Cardiac Surgery Patients in New Clinical Study Results

$

0

0

Reduction in chest tube clogging and take back for bleeding shown in randomized prospective clinical trial with PleuraFlow ACT System IRVINE, CA —March 30, 2021 ClearFlow, Inc., a medical device company based in Irvine, California, has announced positive clinical trial results published in the peer-reviewed Journal of Cardiothoracic Surgery. The findings are reported by cardiac surgeons at the Montreal Heart Institute, in Montreal, Quebec, Canada in the article, “Active clearance vs conventional management of chest tubes after cardiac surgery: a randomized controlled study.” The randomized prospective trial evaluated the use of the PleuraFlow® Active Clearance Technology® (ACT®) System in the effective reduction of retained blood complications in heart surgery patients

The post Randomized Clinical Trial Results Confirm PleuraFlow Reduces Take Back for Bleeding in Cardiac Surgery Patients appeared first on ClearFlow.